Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets continue to slide
Fri, 25 Jul 11:30 am

Backed by heavy selling activity across the indices, the Indian stock markets have remained have remained below the dotted line during the morning trading session. Barring stocks from FMCG and healthcare sectors, all the sectoral indices are witnessing selling pressures. Stocks from IT and Metal sectors are the leading losers.

The BSE-Sensex is trading down 106 points. The NSE-Nifty is trading down 33 points. The BSE Mid Cap index is trading down 0.62% and the BSE Small Cap index is trading down 1.05%. The rupee is trading at 60.02 to the US dollar.

Modi government seems to be facing tough time day by day. As per the financial daily, India's Human Development Index (HDI) has remained in the doldrums for yet another year. The United Nations Development Program (UNDP) has released its 2014 HDI report. India's rank has remained static at 135 compared to last year. Other BRICS nations rank above India. The report has reiterated just how badly India has fared on its development goals even as it has increased per capita incomes four times since the 1980s in PPP terms. During the same time India's HDI ranking has improved only 1.6 times. This reflects the growing disparity between the well off and the poor in India. Even in terms of pace of improvement, India ranks lower than many developing nations.

Indian pharma stocks are trading mixed today. Wockhardt Ltd and Glenmark pharma are among the stock leading the gainers while Biocon Ltd and Aurobindo are among the stocks leading the losers. Glenmark pharma has declared its June quarter financial year 2015 results (1QFY15). The company reported topline growth of 20% YoY for 1QFY15. The company also received licensing income of Rs 300 m during the quarter. Excluding this income, the sales growth was approx 17.6% YoY. The top line growth was largely led by growth in India, Europe and RoW markets. The US geography witnessed modest growth of 9% YoY, during the quarter. EBITDA increased by 38.16% YoY and the net profits were up by 43.65% YoY. Glenmark is trading up by 5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets continue to slide". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.